Both globally and locally we have many successful long-term partnerships in in- and out-licensing. These include the launch of new chemical entities as well as taking over distribution rights to existing products from multi-national partners.

A Long-term and Personalised Relationship

The scope and complexity of science today requires an open and co-operative network between all stakeholders in research. This is why we are always actively searching for research partnerships, with academic organisations as well as other pharmaceutical groups and biotechnology companies. Choosing a partnership with us means long-term investment, via our foundation-based structure. It means choosing scientific and medical excellence with our top scientists and extensive clinical expert network. Each partnership is unique, and creates a personalised relationship.

What We Can Offer You

  • A long-term and personalised relationship.
  • Proven track record in clinical development, including large-scale outcome studies
  • Strong network of contacts and an excellent reputation with top experts in the pharmaceutical sector.
  • Considerable R&D capabilities, including 1900 exclusively dedicated staff in France and 16 International Centres for Therapeutic Research.
  • High level of commitment and scientific expertise.
  • Partnerships managed by dedicated teams of alliance professionals certified by ASAP.
  • Presence or commercial activity in more than 90 countries.

What We Are Looking For

We are seeking opportunities in our 5 areas of research and development: Cardiovascular Diseases, Cancer, Diabetes Neuropsychiatric Diseases, Immune-Inflammatory Diseases

  • We are interested in all innovative “best-in-class” products, from the target stage to late-stage clinical trials, provided they bring true therapeutic innovation to areas of unmet needs.
  • We are also interested in licensing marketed, or near-market, products that complement our existing portfolio.
  • Out-licensing: We are looking for partners in the United States and Japan to licence some of our drug candidates and medicinal products, and global partners for non-strategic products.
  • What types of agreements? – Global rights with or without the United States and Japan – Local and regional agreements – R&D collaborations starting immediately or after option exercise.

Our Alliances

Worldwide we currently have more than 50 active alliances with biotech and pharmaceutical companies across all our areas of activity:

Servier Australia is delighted that two key collaborations are with local centres of excellence:

Walter and Eliza Hall Institute of Medical Research (WEHI)

Servier has established a collaborative partnership with the Walter and Eliza Hall Institute to facilitate the development of new agents that could be effective in treating several types of cancer, particularly blood cancers.

WEHI is the research powerhouse of the Victorian Comprehensive Cancer Centre, an alliance of leading Victorian hospitals and research centres committed to controlling cancer.

Researchers at WEHI, led by Associate Professor Guillaume Lessene, are working in collaboration with a team at the Alfred Hospital in Melbourne, to test the Servier compound – which targets proteins of the BCL2 family.

Early findings have been published in the journal Nature.

“Walter and Eliza Hall Institute researchers made the initial discovery explaining how BCL-2 played a role in cancer more than 20 years ago. MCL1, part of the BCL2 family, is important for many cancers because it is a pro-survival protein, that allows the cancerous cells to evade the process of programmed cell death which normally removes cancer cells from the body,” Associate Professor Lessene said.

The research was supported through a research collaboration with Servier and a number of other agencies.

Monash Institute of Pharmaceutical Sciences (MIPS)

The collaboration between Servier and MIPS makes use of world-leading capability in the identification of novel G Protein-Coupled Receptor (GPCR) targets and design of new chemical entities which modulate GPCR activity. GPCR represents the largest superfamily of all receptors (approximately 2% of the human genome) and are the targets for approximately 40% of modern medicines.)

MIPS is Australia’s leading faculty of pharmacy and pharmaceutical sciences, being at the forefront of both research and education in the field. Monash is ranked second in world university rankings for pharmacy and pharmacology for 2018; a repeat of 2017.

“We are excited to be working with leading Australian experts in GPCR research and to have the opportunity of being involved in the advancement and translation of GPCR-based research into new therapeutic agents for major human diseases.”

Professor Bill Charman Founding Director of MIPS, and Dean, Faculty of Pharmacy and Pharmaceutical Sciences.